Lipid-lowering agents and hepatotoxicity

Michael Demyen, Kawtar Alkhalloufi, Nikolaos T. Pyrsopoulos

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Lipid-lowering therapy is increasingly being used in patients for a variety of diseases, the most important being secondary prevention of cardiovascular disease. Many lipid-lowering drugs carry side effects that include elevations in hepatic function tests and liver toxicity. In many cases, these drugs are not prescribed or they are underprescribed because of fears of injury to the liver. This article attempts to review key trials with respect to the hepatotoxicity of these drugs. Recommendations are also provided with respect to the selection of low-risk patients and strategies to lower the risk of hepatotoxicity when prescribing these medications.

Original languageEnglish (US)
Pages (from-to)699-714
Number of pages16
JournalClinics in Liver Disease
Issue number4
StatePublished - Nov 2013

All Science Journal Classification (ASJC) codes

  • Hepatology


  • Drug-induced liver injury
  • Hepatotoxicity
  • Lipid-lowering agents
  • Statins

Fingerprint Dive into the research topics of 'Lipid-lowering agents and hepatotoxicity'. Together they form a unique fingerprint.

Cite this